{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:57:15Z","timestamp":1791269835107,"version":"4.1.0"},"reference-count":121,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Since the 1950s, understanding of antipsychotic activity in schizophrenia has been largely grounded in the dopamine (DA) hypothesis. Most antipsychotics approved for schizophrenia interact with D2 DA receptors as an important part of their mechanism of action. While antipsychotics blocking D2 DA receptors can be effective for positive symptoms of schizophrenia, none are approved by regulatory authorities for predominant negative or cognitive symptoms. Moreover, many of these agents induce a range of problematic side effects related to D2 DA receptor blockade (eg, drug-induced parkinsonism, akathisia, tardive dyskinesia, hyperprolactinemia and related sexual side effects, sedation). This has prompted the search for novel mechanisms with improved efficacy and tolerability based on evidence supporting involvement of other neurotransmitter systems in schizophrenia pathophysiology, including acetylcholine, gamma-aminobutyric acid, and glutamate. Among these options, targeting muscarinic receptors emerged as a promising treatment strategy. In September 2024, the U.S. Food and Drug Administration approved xanomeline and trospium chloride for treatment of adults with schizophrenia based on results from three 5-week, randomized, double-blind, placebo-controlled trials and two 52-week open-label trials. In the placebo-controlled trials, xanomeline\/trospium reduced symptoms of schizophrenia, was generally well tolerated, and was not associated with clinically meaningful motor symptoms, hyperprolactinemia, sexual side effects, or weight gain compared with placebo. The long-term safety of xanomeline\/trospium was also confirmed in two 52-week, open-label trials. This paper reviews the preclinical and clinical rationale for muscarinic receptor activation as a treatment for schizophrenia and the efficacy, safety, and tolerability profile of xanomeline\/trospium.<\/jats:p>","DOI":"10.1093\/ijnp\/pyaf015","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T13:28:01Z","timestamp":1741440481000},"source":"Crossref","is-referenced-by-count":17,"title":["From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1\/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials"],"prefix":"10.1093","volume":"28","author":[{"given":"Jonathan M","family":"Meyer","sequence":"first","affiliation":[{"name":"Department of Psychiatry,\u00a0University of California, San Diego , San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kramer","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Vuocolo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Kaul","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C","family":"Miller","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"2025100309022761200_CIT0001","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N Engl J Med."},{"key":"2025100309022761200_CIT0002","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet."},{"key":"2025100309022761200_CIT0003","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S2215-0366(21)00029-8","article-title":"Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark","volume":"8","author":"Weye","year":"2021","journal-title":"Lancet Psychiatry."},{"key":"2025100309022761200_CIT0004","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","journal-title":"Lancet."},{"key":"2025100309022761200_CIT0005","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry."},{"key":"2025100309022761200_CIT0006","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"2025100309022761200_CIT0007","doi-asserted-by":"publisher","first-page":"e24597","DOI":"10.1371\/journal.pone.0024597","article-title":"Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder","volume":"6","author":"Laursen","year":"2011","journal-title":"PLoS One."},{"key":"2025100309022761200_CIT0008","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess early mortality in schizophrenia","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu Rev Clin Psychol."},{"key":"2025100309022761200_CIT0009","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry."},{"key":"2025100309022761200_CIT0010","doi-asserted-by":"crossref","DOI":"10.1017\/9781108975292","volume-title":"Stahl\u2019s Essential Psychopharmacology.","author":"Stahl","year":"2021","edition":"5th ed"},{"key":"2025100309022761200_CIT0011","doi-asserted-by":"crossref","first-page":"SU21024IP21021","DOI":"10.4088\/JCP.SU21024IP1","article-title":"Emerging treatments in schizophrenia","volume":"83","author":"Correll","year":"2022","journal-title":"J Clin Psychiatry."},{"key":"2025100309022761200_CIT0012","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci Biobehav Rev."},{"key":"2025100309022761200_CIT0013","doi-asserted-by":"publisher","first-page":"108236","DOI":"10.1016\/j.pharmthera.2022.108236","article-title":"Clozapine\u2019s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia","volume":"236","author":"de Bartolomeis","year":"2022","journal-title":"Pharmacol Ther."},{"key":"2025100309022761200_CIT0014","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry."},{"key":"2025100309022761200_CIT0015","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/7854_2022_400","article-title":"Cholinergic functioning, cognition, and anticholinergic medication burden in schizophrenia","volume":"63","author":"Joshi","year":"2023","journal-title":"Curr Top Behav Neurosci."},{"key":"2025100309022761200_CIT0016","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuron.2016.06.014","article-title":"Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons","volume":"91","author":"Kharkwal","year":"2016","journal-title":"Neuron."},{"key":"2025100309022761200_CIT0017","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"2025100309022761200_CIT0018","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/jcp.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"2025100309022761200_CIT0019","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry."},{"key":"2025100309022761200_CIT0020","first-page":"171","article-title":"Tetrabenazine (nitoman) in the treatment of psychoses. With a discussion on the central mode of action of tetrabenazine and reserpine","volume":"39:Suppl170","author":"Lingjaerde","year":"1963","journal-title":"Acta Psychiatr Scand."},{"key":"2025100309022761200_CIT0021","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/BF02245602","article-title":"Mechanisms of action of atypical antipsychotic drugs: a critical analysis","volume":"124","author":"Kinon","year":"1996","journal-title":"Psychopharmacology (Berl)."},{"key":"2025100309022761200_CIT0022","doi-asserted-by":"publisher","first-page":"2045125320937575","DOI":"10.1177\/2045125320937575","article-title":"Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment","volume":"10","author":"Musco","year":"2020","journal-title":"Ther Adv Psychopharmacol."},{"key":"2025100309022761200_CIT0023","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci."},{"key":"2025100309022761200_CIT0024","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis","volume":"44","author":"McCutcheon","year":"2018","journal-title":"Schizophr Bull."},{"key":"2025100309022761200_CIT0025","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia","volume":"12","author":"Raedler","year":"2007","journal-title":"Mol Psychiatry."},{"key":"2025100309022761200_CIT0026","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","article-title":"Muscarinic receptor activators as novel treatments for schizophrenia","volume":"96","author":"Paul","year":"2024","journal-title":"Biol Psych."},{"key":"2025100309022761200_CIT0027","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am J Psychiatry."},{"key":"2025100309022761200_CIT0028","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol Sci."},{"key":"2025100309022761200_CIT0029","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.schres.2014.10.011","article-title":"GABA abnormalities in schizophrenia: a methodological review of in vivo studies","volume":"167","author":"Taylor","year":"2015","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fpsyt.2017.00118","article-title":"GABAergic mechanisms in schizophrenia: linking postmortem and in vivo studies","volume":"8","author":"de Jonge","year":"2017","journal-title":"Front Psychiatry."},{"key":"2025100309022761200_CIT0031","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"2025100309022761200_CIT0032","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41398-022-02253-w","article-title":"Glutamatergic dysfunction in schizophrenia","volume":"12","author":"Kruse","year":"2022","journal-title":"Transl Psychiatry."},{"key":"2025100309022761200_CIT0033","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry."},{"key":"2025100309022761200_CIT0034","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin Neurosci."},{"key":"2025100309022761200_CIT0035","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1192\/bjp.107.447.287","article-title":"A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia","volume":"107","author":"Ashcroft","year":"1961","journal-title":"J Ment Sci."},{"key":"2025100309022761200_CIT0036","doi-asserted-by":"publisher","first-page":"107510","DOI":"10.1016\/j.phrs.2024.107510","article-title":"IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia","volume":"210","author":"Dean","year":"2024","journal-title":"Pharmacol Res."},{"key":"2025100309022761200_CIT0037","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1749-6632.1957.tb40764.x","article-title":"The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain","volume":"66","author":"Pfeiffer","year":"1957","journal-title":"Ann N Y Acad Sci."},{"key":"2025100309022761200_CIT0038","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1021\/jm00090a019","article-title":"Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines","volume":"35","author":"Sauerberg","year":"1992","journal-title":"J Med Chem."},{"key":"2025100309022761200_CIT0039","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/sj.bjp.0702463","article-title":"Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry","volume":"126","author":"Wood","year":"1999","journal-title":"Br J Pharmacol."},{"key":"2025100309022761200_CIT0040","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neuropharm.2018.01.028","article-title":"Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases","volume":"136","author":"Felder","year":"2018","journal-title":"Neuropharmacology."},{"key":"2025100309022761200_CIT0041","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol."},{"key":"2025100309022761200_CIT0042","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry."},{"key":"2025100309022761200_CIT0043","first-page":"740","article-title":"Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials","volume":"11","author":"McArthur","year":"2010","journal-title":"Curr Opin Investig Drugs."},{"key":"2025100309022761200_CIT0044","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0920-9964(99)00138-3","article-title":"Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice","volume":"42","author":"Shannon","year":"2000","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0045","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J Pharmacol Exp Ther."},{"key":"2025100309022761200_CIT0046","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/sj.npp.1300151","article-title":"The muscarinic M1\/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys","volume":"28","author":"Andersen","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"2025100309022761200_CIT0047","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1523\/JNEUROSCI.0370-11.2011","article-title":"Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline","volume":"31","author":"Dencker","year":"2011","journal-title":"J Neurosci."},{"key":"2025100309022761200_CIT0048","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","article-title":"Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice","volume":"603","author":"Woolley","year":"2009","journal-title":"Eur J Pharmacol."},{"key":"2025100309022761200_CIT0049","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1017\/S1461145710001549","article-title":"The M\u2081\/M\u2084 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"Int J Neuropsychopharmacol."},{"key":"2025100309022761200_CIT0050","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.neuropharm.2017.09.012","article-title":"Positive allosteric modulation of M(1) and M(4) muscarinic receptors as potential therapeutic treatments for schizophrenia","volume":"136","author":"Yohn","year":"2018","journal-title":"Neuropharmacology."},{"key":"2025100309022761200_CIT0051","doi-asserted-by":"crossref","first-page":"1421554","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M1 and M4 activators for the treatment of cognitive impairment with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front Psychiatry."},{"key":"2025100309022761200_CIT0052","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","article-title":"The role of D2-autoreceptors in regulating dopamine neuron activity and transmission","volume":"282","author":"Ford","year":"2014","journal-title":"Neuroscience."},{"key":"2025100309022761200_CIT0053","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.biopsych.2006.08.050","article-title":"Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia","volume":"61","author":"Scarr","year":"2007","journal-title":"Biol Psychiatry."},{"key":"2025100309022761200_CIT0054","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0006-3223(00)00918-5","article-title":"Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation","volume":"48","author":"Crook","year":"2000","journal-title":"Biol Psychiatry."},{"key":"2025100309022761200_CIT0055","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.schres.2013.01.023","article-title":"Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia","volume":"146","author":"Scarr","year":"2013","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0056","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1038\/tp.2013.3","article-title":"Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA","volume":"3","author":"Scarr","year":"2013","journal-title":"Transl Psychiatry."},{"key":"2025100309022761200_CIT0057","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0166-2236(98)01361-7","article-title":"Acetylcholine in mind: a neurotransmitter correlate of consciousness","volume":"22","author":"Perry","year":"1999","journal-title":"Trends Neurosci."},{"key":"2025100309022761200_CIT0058","doi-asserted-by":"publisher","first-page":"15312","DOI":"10.1073\/pnas.261583798","article-title":"Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice","volume":"98","author":"Gerber","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025100309022761200_CIT0059","doi-asserted-by":"publisher","first-page":"10483","DOI":"10.1073\/pnas.96.18.10483","article-title":"Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice","volume":"96","author":"Gomeza","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025100309022761200_CIT0060","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1756-6606-5-10","article-title":"M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition","volume":"5","author":"Koshimizu","year":"2012","journal-title":"Mol Brain."},{"key":"2025100309022761200_CIT0061","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/TACG.S247174","article-title":"Association of cholinergic muscarinic M4 receptor gene polymorphism with schizophrenia","volume":"13","author":"Pozhidaev","year":"2020","journal-title":"Appl Clin Genet."},{"key":"2025100309022761200_CIT0062","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.schres.2012.02.011","article-title":"Muscarinic M1 receptor sequence: preliminary studies on its effects on cognition and expression","volume":"138","author":"Scarr","year":"2012","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0063","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.pscychresns.2015.09.004","article-title":"The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia","volume":"234","author":"Cropley","year":"2015","journal-title":"Psychiatry Res."},{"key":"2025100309022761200_CIT0064","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"7","author":"Dean","year":"2002","journal-title":"Mol Psychiatry."},{"key":"2025100309022761200_CIT0065","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1176\/appi.ajp.160.1.118","article-title":"In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia","volume":"160","author":"Raedler","year":"2003","journal-title":"Am J Psychiatry."},{"key":"2025100309022761200_CIT0066","doi-asserted-by":"publisher","first-page":"112989","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatry Res."},{"key":"2025100309022761200_CIT0067","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/mp.2008.28","article-title":"Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia","volume":"14","author":"Scarr","year":"2009","journal-title":"Mol Psychiatry."},{"key":"2025100309022761200_CIT0068","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","article-title":"M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies","volume":"18","author":"Tzavara","year":"2004","journal-title":"FASEB J."},{"key":"2025100309022761200_CIT0069","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/febs.15496","article-title":"Roles of dopamine and glutamate co-release in the nucleus accumbens in mediating the actions of drugs of abuse","volume":"288","author":"Buck","year":"2021","journal-title":"FEBS J."},{"key":"2025100309022761200_CIT0070","article-title":"Acetylcholine as a regulator of dopamine pathways:","author":"Weiden"},{"key":"2025100309022761200_CIT0071","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1113\/jphysiol.2014.275453","article-title":"Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition","volume":"592","author":"Yi","year":"2014","journal-title":"J Physiol."},{"key":"2025100309022761200_CIT0072","doi-asserted-by":"publisher","first-page":"ENEURO.0208","DOI":"10.1523\/ENEURO.0208-18.2018","article-title":"Cell type- and layer-specific muscarinic potentiation of excitatory synaptic drive onto parvalbumin neurons in mouse prefrontal cortex","volume":"5","author":"Tikhonova","year":"2018","journal-title":"eNeuro"},{"key":"2025100309022761200_CIT0073","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000368279","article-title":"The nucleus accumbens: a comprehensive review","volume":"93","author":"Salgado","year":"2015","journal-title":"Stereotact Funct Neurosurg."},{"key":"2025100309022761200_CIT0074","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P T."},{"key":"2025100309022761200_CIT0075","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1046\/j.1460-9568.2003.02511.x","article-title":"Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat","volume":"17","author":"Forster","year":"2003","journal-title":"Eur J Neurosci."},{"key":"2025100309022761200_CIT0076","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1503\/jpn.170202","article-title":"Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia","volume":"43","author":"Scarr","year":"2018","journal-title":"J Psychiatry Neurosci."},{"key":"2025100309022761200_CIT0077","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.schres.2020.02.001","article-title":"The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - a systematic review of magnetic resonance spectroscopy studies","volume":"249","author":"Reddy-Thootkur","year":"2022","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0078","doi-asserted-by":"publisher","first-page":"116244","DOI":"10.1016\/j.neuroimage.2019.116244","article-title":"Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm","volume":"204","author":"Spurny","year":"2020","journal-title":"Neuroimage."},{"key":"2025100309022761200_CIT0079","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/schbul\/sbs062","article-title":"Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling","volume":"38","author":"Tamminga","year":"2012","journal-title":"Schizophr Bull."},{"key":"2025100309022761200_CIT0080","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1152\/jn.00686.2010","article-title":"M1 and M4 receptors modulate hippocampal pyramidal neurons","volume":"105","author":"Dasari","year":"2011","journal-title":"J Neurophysiol."},{"key":"2025100309022761200_CIT0081","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/cne.24409","article-title":"Immunolocalization of muscarinic M1 receptor in the rat medial prefrontal cortex","volume":"526","author":"Oda","year":"2018","journal-title":"J Comp Neurol."},{"key":"2025100309022761200_CIT0082","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1523\/JNEUROSCI.23-04-01159.2003","article-title":"Muscarinic potentiation of GABA(A) receptor currents is gated by insulin signaling in the prefrontal cortex","volume":"23","author":"Ma","year":"2003","journal-title":"J Neurosci."},{"key":"2025100309022761200_CIT0083","doi-asserted-by":"publisher","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"J Neurosci."},{"key":"2025100309022761200_CIT0084","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nchembio.2007.55","article-title":"An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission","volume":"4","author":"Shirey","year":"2008","journal-title":"Nat Chem Biol."},{"key":"2025100309022761200_CIT0085","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1021\/cn500128b","article-title":"Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents","volume":"5","author":"Bubser","year":"2014","journal-title":"ACS Chem Neurosci."},{"key":"2025100309022761200_CIT0086","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000357682","article-title":"Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats","volume":"93","author":"Galloway","year":"2014","journal-title":"Pharmacology."},{"key":"2025100309022761200_CIT0087","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neuropharm.2017.07.013","article-title":"Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M(4) PAM VU0467154","volume":"128","author":"Gould","year":"2018","journal-title":"Neuropharmacology."},{"key":"2025100309022761200_CIT0088","first-page":"Poster 242.209","article-title":"NS-136, a selective muscarinic receptor positive allosteric modulator (PAM) for the treatment of schizophrenia","author":"Wu"},{"key":"2025100309022761200_CIT0089","doi-asserted-by":"publisher","first-page":"108754","DOI":"10.1016\/j.neuropharm.2021.108754","article-title":"Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer\u2019s disease and schizophrenia in rhesus monkey","volume":"197","author":"Lange","year":"2021","journal-title":"Neuropharmacology."},{"key":"2025100309022761200_CIT0090","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology."},{"key":"2025100309022761200_CIT0091","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/B978-0-12-819975-6.00010-8","article-title":"Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson\u2019s disease","volume":"179","author":"Wilson","year":"2021","journal-title":"Handb Clin Neurol."},{"key":"2025100309022761200_CIT0092","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat Neurosci."},{"key":"2025100309022761200_CIT0093","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00008877-199511000-00005","article-title":"Effects of selective antagonism or depletion of the cholinergic system on visual discrimination performance in rats","volume":"6","author":"Drinkenburg","year":"1995","journal-title":"Behav Pharmacol."},{"key":"2025100309022761200_CIT0094","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0091-3057(88)90490-x","article-title":"The effect of pirenzepine on spatial learning in the Morris Water Maze","volume":"30","author":"Hunter","year":"1988","journal-title":"Pharmacol Biochem Behav."},{"key":"2025100309022761200_CIT0095","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","article-title":"Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice","volume":"6","author":"Gould","year":"2015","journal-title":"ACS Chem Neurosci."},{"key":"2025100309022761200_CIT0096","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/hipo.22732","article-title":"Effects of M1 and M4 activation on excitatory synaptic transmission in CA1","volume":"27","author":"Thorn","year":"2017","journal-title":"Hippocampus."},{"key":"2025100309022761200_CIT0097","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"2025100309022761200_CIT0098","doi-asserted-by":"publisher","first-page":"136240","DOI":"10.1016\/j.neulet.2021.136240","article-title":"Therapeutic potential of TAK-071, a muscarinic M(1) receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia","volume":"764","author":"Kurimoto","year":"2021","journal-title":"Neurosci Lett."},{"key":"2025100309022761200_CIT0099","doi-asserted-by":"publisher","article-title":"Muscarinic receptor pharmacology and circuitry for the modulation of cognition","author":"Bubser","DOI":"10.1007\/978-3-642-23274-9_7"},{"key":"2025100309022761200_CIT0100","doi-asserted-by":"publisher","first-page":"e2216792120","DOI":"10.1073\/pnas.2216792120","article-title":"M(1)-selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primates","volume":"120","author":"Hassani","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025100309022761200_CIT0101","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol."},{"key":"2025100309022761200_CIT0102","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1532-5415.2010.02988.x","article-title":"Trospium chloride is undetectable in the older human central nervous system","volume":"58","author":"Staskin","year":"2010","journal-title":"J Am Geriatr Soc."},{"key":"2025100309022761200_CIT0103","article-title":"Xanomeline plus trospium: a novel strategy to enhance pro-muscarinic efficacy and mitigate peripheral side effects","author":"Kavoussi"},{"key":"2025100309022761200_CIT0104","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med."},{"key":"2025100309022761200_CIT0105","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet."},{"key":"2025100309022761200_CIT0106","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry."},{"key":"2025100309022761200_CIT0107","article-title":"The muscarinic agnist xanomeline demonstrates standalone activity and augments clinical antipsychotics in rodent behavioral models of pychosis","author":"McKinzie"},{"key":"2025100309022761200_CIT0108","doi-asserted-by":"publisher","first-page":"23nr15240","DOI":"10.4088\/JCP.23nr15240","article-title":"Rationale for adjunctive treatment targeting multiple mechanisms in schizophrenia","volume":"85","author":"Kinon","year":"2024","journal-title":"J Clin Psychiatry."},{"key":"2025100309022761200_CIT0109","first-page":"Poster M74","article-title":"Efficacy of KarXT (xanomeline-trospium) in schizophrenia: pooled results from the randomized, double-blind, placebo-controlled EMERGENT trials","author":"Kaul"},{"key":"2025100309022761200_CIT0110","first-page":"Poster T186","article-title":"KarXT (xanomeline-trospium) demonstrates broad efficacy in people with schizophrenia across a wide range of demographic subgroups: pooled results from the 3 randomized, double-blind, placebo-controlled EMERGENT trials","author":"Kaul"},{"key":"2025100309022761200_CIT0111","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","article-title":"Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials","volume":"274","author":"Horan","year":"2024","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0112","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.schres.2018.08.020","article-title":"Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data","volume":"204","author":"Earley","year":"2019","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0113","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4088\/jcp.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry."},{"key":"2025100309022761200_CIT0114","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2003.11.008","article-title":"The heterogeneity of schizophrenia in disease states","volume":"71","author":"Mohr","year":"2004","journal-title":"Schizophr Res."},{"key":"2025100309022761200_CIT0115","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"2025100309022761200_CIT0116","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl Psychiatry."},{"key":"2025100309022761200_CIT0117","article-title":"The impact of KarXT on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials","author":"Horan","journal-title":"Am J Psychiatry."},{"key":"2025100309022761200_CIT0118","first-page":"Poster F264","article-title":"Maintenance of efficacy of KarXT (xanomeline and trospium) in schizophrenia","author":"Kaul"},{"key":"2025100309022761200_CIT0119","first-page":"Poster T189","article-title":"Safety and tolerability of KarXT (xanomeline-trospium): pooled results from the randomized, double-blind, placebo-controlled EMERGENT trials","author":"Brannan"},{"key":"2025100309022761200_CIT0120","first-page":"Poster F74","article-title":"Long-term safety of KarXT (xanomeline and trospium) in schizophrenia","author":"Marcus"},{"key":"2025100309022761200_CIT0121","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","article-title":"Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis","volume":"19","author":"Barton","year":"2020","journal-title":"Expert Opin Drug Saf."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf015\/62343407\/pyaf015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/4\/pyaf015\/62343407\/pyaf015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/4\/pyaf015\/62343407\/pyaf015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:02:35Z","timestamp":1759496555000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf015\/8063932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf015","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,8]]},"article-number":"pyaf015"}}